Drugs that contain Cilastatin Sodium; Imipenem; Relebactam
1. List of Recarbrio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Jul 16, 2029 |
NCE-1 date: 2028-07-16
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...
Dosage: POWDER;INTRAVENOUS
RECARBRIO family patents
4
United States
3
Japan
3
Lithuania
2
Spain
2
Hong Kong
2
Denmark
2
RS
2
Poland
2
China
2
Croatia
2
Korea, Republic of
2
Cyprus
2
Portugal
2
Ecuador
2
Netherlands
2
Slovenia
2
Hungary
2
European Union
1
Dominican Republic
1
Malaysia
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Norway
1
ME
1
Nicaragua
1
Honduras
1
New Zealand
1
Israel
1
Mexico
1
Australia
1
Costa Rica
1
South Africa
1
Colombia
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic